RVL Pharmaceuticals plc (RVLPQ)

Market Cap	111.00 -100.0%
Revenue (ttm)	36.92M +5.6%
Net Income	-68.27M
EPS	-0.70
Shares Out	111.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	6,167
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	47.40
RSI	48.35
Earnings Date	n/a

About RVL Pharmaceuticals

RVL Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, Argentina, and Hungary. It focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and chan...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Brian Markison
• Employees: 125
• Stock Exchange: OTCMKTS
• Ticker Symbol: RVLPQ